Dynamic control of type I IFN signalling by an integrated network of negative regulators

Trends in Immunology

Volumn 36, Issue 3, 2015, Pages 150-160

  Porritt, Rebecca A ^a,b   Hertzog, Paul J ^a  

^a MONASH UNIVERSITY   (Australia)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cytokine; Interferon; JAK; SOCS; STAT

Indexed keywords

BETA INTERFERON; CASEIN KINASE IALPHA; COLONY STIMULATING FACTOR 1; CRK LIKE PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE R; PROTEIN P53; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; CYTOKINE RECEPTOR; INTERLEUKIN DERIVATIVE; MICRORNA; SIGNAL PEPTIDE; SMAD PROTEIN; UBIQUITIN PROTEIN LIGASE;

CD8+ T LYMPHOCYTE; DNA METHYLATION; GENE EXPRESSION; INTERFERON PRODUCTION; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; WEST NILE FEVER; DENDRITIC CELL; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; VIRUS;

DENDRITIC CELLS; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERLEUKINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SMAD PROTEINS; UBIQUITIN-PROTEIN LIGASES; VIRUSES;

EID: 84924265294     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.02.002     Document Type: Review

References (114)

1. O'Connell R.M., et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004, 200:437-445.
2. Rice G.I., et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013, 12:1159-1169.
3. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Upsala J. Med. Sci. 2011, 116:227-237.
4. Friedman R.M. Clinical uses of interferons. Br. J. Clin. Pharmacol. 2008, 65:158-162.
5. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112S-121S.
6. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
7. Fung K.Y., et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013, 339:1088-1092.
8. Hamilton J.A., et al. Endogenous IFN-alpha beta suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha. J. Immunol. 1996, 156:2553-2557.
9. Takayanagi H., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749.
10. Leonova K.I., et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E89-E98.
11. Honda K., et al. Regulation of the type I IFN induction: a current view. Int. Immunol. 2005, 17:1367-1378.
12. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
13. Barber G.N. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014, 35:88-93.
14. Zhang Z., et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011, 34:866-878.
15. Zhang Z., et al. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J. Immunol. 2011, 187:4501-4508.
16. Schoggins J.W., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
17. Hervas-Stubbs S., et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17:2619-2627.
18. Conrady C.D., et al. IFN-alpha-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol. 2013, 6:45-55.
19. Simmons D.P., et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 2012, 188:3116-3126.
20. Biron C.A., et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
21. Braun D., et al. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 2002, 14:411-419.
22. Kiefer K., et al. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell Biol. 2012, 90:498-504.
23. Tough D.F. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 2012, 90:492-497.
24. Grimley P.M., et al. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev. 1999, 10:131-157.
25. Park C., et al. Immune response in Stat2 knockout mice. Immunity 2000, 13:795-804.
26. van Boxel-Dezaire A.H., et al. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372.
27. Velichko S., et al. STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. Activation of multiple STATS proceeds through the redundant usage of two tyrosine residues. J. Biol. Chem. 2002, 277:35635-35641.
28. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
29. Fish E.N., Platanias L.C. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol. Cancer Res. 2014, 12:1691-1703.
30. Arimoto K., et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7500-7505.
31. Zinngrebe J., et al. Ubiquitin in the immune system. EMBO Rep. 2014, 15:28-45.
32. Das A., et al. Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication. J. Virol. 2014, 88:3103-3113.
33. Cui J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.
34. Tong Y., et al. Enhanced TLR-induced NF-kappaB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res. 2012, 22:822-835.
35. Li Y., et al. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7945-7950.
36. Tailor P., et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 2007, 27:228-239.
37. Hida S., et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000, 13:643-655.
38. Rajsbaum R., et al. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J. Mol. Biol. 2014, 426:1265-1284.
39. Lee E.G., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
40. Wertz I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699.
41. Meylan E., et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 2004, 5:503-507.
42. Wang Y.Y., et al. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter. FEBS Lett. 2004, 576:86-90.
43. Lin R., et al. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J. Biol. Chem. 2006, 281:2095-2103.
44. Zhang M., et al. TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J. Exp. Med. 2012, 209:1703-1711.
45. Zhang M., et al. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell Res. 2008, 18:1096-1104.
46. Nakhaei P., et al. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog. 2009, 5:e1000650.
47. Zhong H., et al. Ubiquitin-specific proteases 25 negatively regulates virus-induced type I interferon signaling. PLoS ONE 2013, 8:e80976.
48. Hu Y., et al. Guanylate binding protein 4 negatively regulates virus-induced type I IFN and antiviral response by targeting IFN regulatory factor 7. J. Immunol. 2011, 187:6456-6462.
49. Wang J., et al. Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J. Immunol. 2013, 191:3393-3399.
50. You F., et al. PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4. Nat. Immunol. 2009, 10:1300-1308.
51. Lee M.S., et al. OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat. Immunol. 2013, 14:346-355.
52. Ma Z., et al. DDX24 negatively regulates cytosolic RNA-mediated innate immune signaling. PLoS Pathog. 2013, 9:e1003721.
53. Li J., et al. A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. MBio 2013, 4. e00385-e00313.
54. Sugiyama Y., et al. Smad2 and Smad3 are redundantly essential for the suppression of iNOS synthesis in macrophages by regulating IRF3 and STAT1 pathways. Int. Immunol. 2012, 24:253-265.
55. de Weerd N.A., et al. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 2007, 282:20053-20057.
56. Hardy M.P., et al. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001, 97:473-482.
57. Samarajiwa S.A., et al. Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. J. Immunol. 2014, 192:4425-4435.
58. Marijanovic Z., et al. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem. J. 2006, 397:31-38.
59. Zheng H., et al. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol. Cell. Biol. 2011, 31:710-720.
60. Bhattacharya S., et al. Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 2010, 285:2318-2325.
61. Liu J., et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 2009, 5:72-83.
62. Malakhova O.A., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006, 25:2358-2367.
63. Francois-Newton V., et al. USP18 establishes the transcriptional and anti-proliferative interferon alpha/beta differential. Biochem. J. 2012, 446:509-516.
64. Francois-Newton V., et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE 2011, 6:e22200.
65. Basters A., et al. Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15. FEBS J. 2014, 281:1918-1928.
66. Lenschow D.J., et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1371-1376.
67. Sarasin-Filipowicz M., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7034-7039.
68. Zhang X., et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 2015, 517:89-93.
69. Dauphinee S.M., et al. Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infections. Genes Immun. 2014, 15:282-292.
70. You M., et al. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 1999, 19:2416-2424.
71. David M., et al. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 1995, 15:7050-7058.
72. Bourdeau A., et al. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr. Opin. Cell Biol. 2005, 17:203-209.
73. Myers M.P., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 2001, 276:47771-47774.
74. Simoncic P.D., et al. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 2002, 12:446-453.
75. ten Hoeve J., et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 2002, 22:5662-5668.
76. Xu H., et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol. Immunol. 2008, 45:3545-3552.
77. Song M.M., Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 1998, 273:35056-35062.
78. Sakamoto H., et al. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998, 92:1668-1676.
79. Carow B., Rottenberg M.E. SOCS3, a Major Regulator of Infection and Inflammation. Front. Immunol. 2014, 5:58.
80. Starr R., et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14395-14399.
81. Alexander W.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
82. Fenner J.E., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 2006, 7:33-39.
83. de Weerd N.A., et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 2013, 14:901-907.
84. Piganis R.A., et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 2011, 286:33811-33818.
85. Cheon H., et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013, 32:2751-2763.
86. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 2005, 5:593-605.
87. Liu B., et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 2004, 5:891-898.
88. Tahk S., et al. Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11643-11648.
89. Kubota T., et al. PIASy inhibits virus-induced and interferon-stimulated transcription through distinct mechanisms. J. Biol. Chem. 2011, 286:8165-8175.
90. Matsuyama T., et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75:83-97.
91. Taki S. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev. 2002, 13:379-391.
92. Taniguchi T., et al. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-655.
93. Sharma B., et al. Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J. Biol. Chem. 2012, 287:42352-42360.
94. Benkirane M., et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 1997, 16:611-624.
95. Katze M.G. Regulation of the interferon-induced PKR: can viruses cope?. Trends Microbiol. 1995, 3:75-78.
96. Kumar K.U., et al. Double-stranded RNA-activated protein kinase (PKR) is negatively regulated by 60S ribosomal subunit protein L18. Mol. Cell. Biol. 1999, 19:1116-1125.
97. Shalek A.K., et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013, 498:236-240.
98. Zhao M., et al. Stochastic expression of the interferon-beta gene. PLoS Biol. 2012, 10:e1001249.
99. Kim T.K., Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon-beta enhanceosome. Mol. Cell 1997, 1:119-129.
100. Hwang S.Y., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11284-11288.
101. Weiss G., et al. Helicobacter pylori VacA suppresses Lactobacillus acidophilus-induced interferon beta signaling in macrophages via alterations in the endocytic pathway. MBio 2013, 4:e00609-e00612.
102. Heffron R., et al. Hormonal contraceptive use and risk of HIV-1 disease progression. AIDS 2013, 27:261-267.
103. Kambara H., et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res. 2014, 42:10668-10680.
104. Pedersen I.M., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
105. Kohanbash G., Okada H. MicroRNAs and STAT interplay. Semin. Cancer Biol. 2012, 22:70-75.
106. Witwer K.W., et al. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J. Immunol. 2010, 184:2369-2376.
107. Li Y., et al. MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha. Cell. Mol. Immunol. 2012, 9:497-502.
108. Yang C.H., et al. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70:8108-8116.
109. Hou J., et al. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 2009, 183:2150-2158.
110. Collins A.S., et al. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS ONE 2013, 8:e69090.
111. Li A., et al. MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1. Int. J. Biochem. Cell Biol. 2013, 45:858-865.
112. Su C., et al. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol. J. 2011, 8:354.
113. Yao R., et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS ONE 2012, 7:e46082.
114. Heward J.A., Lindsay M.A. Long non-coding RNAs in the regulation of the immune response. Trends Immunol. 2014, 35:408-419.